Fulcrum Price to Book Value from 2010 to 2024
FULC Stock | USD 7.06 0.09 1.26% |
Check Fulcrum Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Fulcrum main balance sheet or income statement drivers, such as Net Interest Income of 1.8 M, Interest Income of 1.8 M or Discontinued Operations of 0.0, as well as many exotic indicators such as Price To Sales Ratio of 155, Dividend Yield of 0.18 or PTB Ratio of 1.67. Fulcrum financial statements analysis is a perfect complement when working with Fulcrum Therapeutics Valuation or Volatility modules.
Fulcrum | Price to Book Value |
About Fulcrum Therapeutics Financial Statements
There are typically three primary documents that fall into the category of financial statements. These documents include Fulcrum Therapeutics income statement, its balance sheet, and the statement of cash flows. Fulcrum Therapeutics investors use historical funamental indicators, such as Fulcrum Therapeutics's Price to Book Value, to determine how well the company is positioned to perform in the future. Although Fulcrum Therapeutics investors may use each financial statement separately, they are all related. The changes in Fulcrum Therapeutics's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Fulcrum Therapeutics's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. We offer a historical overview of the basic patterns found on Fulcrum Therapeutics Financial Statements. Understanding these patterns can help to make the right decision on long term investment in Fulcrum Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Fulcrum Therapeutics, Inc. was Incorporated in 2015 and is headquartered in Cambridge, Massachusetts. Fulcrum Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 104 people.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out the analysis of Fulcrum Therapeutics Correlation against competitors. For information on how to trade Fulcrum Stock refer to our How to Trade Fulcrum Stock guide.You can also try the Portfolio Suggestion module to get suggestions outside of your existing asset allocation including your own model portfolios.
Complementary Tools for Fulcrum Stock analysis
When running Fulcrum Therapeutics' price analysis, check to measure Fulcrum Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Fulcrum Therapeutics is operating at the current time. Most of Fulcrum Therapeutics' value examination focuses on studying past and present price action to predict the probability of Fulcrum Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Fulcrum Therapeutics' price. Additionally, you may evaluate how the addition of Fulcrum Therapeutics to your portfolios can decrease your overall portfolio volatility.
Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges | |
Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. | |
Fundamental Analysis View fundamental data based on most recent published financial statements | |
Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments |
Is Fulcrum Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Fulcrum Therapeutics. If investors know Fulcrum will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Fulcrum Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.59) | Revenue Per Share 0.046 | Quarterly Revenue Growth 0.272 | Return On Assets (0.29) | Return On Equity (0.45) |
The market value of Fulcrum Therapeutics is measured differently than its book value, which is the value of Fulcrum that is recorded on the company's balance sheet. Investors also form their own opinion of Fulcrum Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Fulcrum Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Fulcrum Therapeutics' market value can be influenced by many factors that don't directly affect Fulcrum Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Fulcrum Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Fulcrum Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Fulcrum Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.